Davis Kimberly, Yount Susan, Wagner Lynne, Cella David
Georgetown University Medical Center, Washington, DC 20007, USA.
Clin Adv Hematol Oncol. 2004 Aug;2(8):533-40.
The 5-year survival rate for lung cancer has been and remains very low, and patient experience is characterized by a heavy symptom burden leading to poorer health-related quality of life (HRQL). In light of these facts, treatment remains primarily palliative with a focus on improving quality of life, particularly through symptom management. Increasingly, clinical research has evaluated both traditional clinical endpoints as well as quality of life as primary outcome variables. This is due in part to recent data in which patient-reported health data have been found to have prognostic value in lung cancer. This paper reviews the literature to date about lung cancer survivors, HRQL conclusions from recent clinical trials, and several barriers to the incorporation of HRQL information into daily clinical practice. Finally, we describe some recent clinical applications of the integration of HRQL information into routine clinical practice with advanced lung cancer patients.
肺癌的5年生存率一直很低，目前依然如此，患者的经历特点是症状负担沉重，导致健康相关生活质量（HRQL）较差。鉴于这些事实，治疗仍主要是姑息性的，重点是改善生活质量，特别是通过症状管理。越来越多的临床研究既评估了传统临床终点，也将生活质量作为主要结局变量进行评估。部分原因是最近的数据表明，患者报告的健康数据在肺癌中具有预后价值。本文回顾了迄今为止关于肺癌幸存者的文献、近期临床试验得出的HRQL结论，以及将HRQL信息纳入日常临床实践的几个障碍。最后，我们描述了将HRQL信息整合到晚期肺癌患者常规临床实践中的一些最新临床应用。
